DENDREON CORP
S-1/A, EX-27.2, 2000-06-15
PHARMACEUTICAL PREPARATIONS
Previous: DENDREON CORP, S-1/A, EX-27.1, 2000-06-15
Next: CBCT BANCSHARES INC, SB-2/A, 2000-06-15



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS RESTATED FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
EXTRACTED FROM FORM S-1 REGISTRATION STATEMENT AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000

<S>                             <C>                     <C>                     <C>
<PERIOD-TYPE>                   YEAR                   YEAR                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-1998             DEC-31-1997
<PERIOD-START>                             JAN-01-1999             JAN-01-1998             JAN-01-1997
<PERIOD-END>                               DEC-31-1999             DEC-31-1998             DEC-31-1997
<CASH>                                           7,085                   6,883                     762
<SECURITIES>                                     6,728                   3,047                   7,461
<RECEIVABLES>                                      833                     344                     532
<ALLOWANCES>                                         0                      25                       0
<INVENTORY>                                          0                       0                       0
<CURRENT-ASSETS>                                15,202                  10,408                   8,963
<PP&E>                                           3,751                   3,198                   2,563
<DEPRECIATION>                                   2,252                   2,064                   1,718
<TOTAL-ASSETS>                                  17,375                  12,038                   9,910
<CURRENT-LIABILITIES>                            5,464                   3,943                   1,492
<BONDS>                                              0                       0                       0
                                0                       0                       0
                                         12                       9                       8
<COMMON>                                             1                       1                       1
<OTHER-SE>                                       5,556                   2,769                   8,297
<TOTAL-LIABILITY-AND-EQUITY>                    17,375                  12,038                   9,910
<SALES>                                              0                       0                       0
<TOTAL-REVENUES>                                 3,719                     866                     793
<CGS>                                                0                       0                       0
<TOTAL-COSTS>                                   16,332                  10,957                   8,184
<OTHER-EXPENSES>                                     0                       2                       0
<LOSS-PROVISION>                                     0                       0                       0
<INTEREST-EXPENSE>                                 351                      41                      47
<INCOME-PRETAX>                               (12,518)                 (9,773)                 (7,163)
<INCOME-TAX>                                         0                     600                       0
<INCOME-CONTINUING>                           (12,518)                (10,373)                 (7,163)
<DISCONTINUED>                                       0                       0                       0
<EXTRAORDINARY>                                      0                       0                       0
<CHANGES>                                            0                       0                       0
<NET-INCOME>                                  (12,518)                (10,373)                 (7,163)
<EPS-BASIC>                                    (13.54)                 (16.48)                 (21.37)
<EPS-DILUTED>                                  (13.54)                 (16.48)                 (21.37)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission